Multiantibody Strategies for HIV

Table 1

Broadly neutralizing monoclonal antibodies (bnMAbs) against HIV.

Epitope	bnMAb	Discovery method	Median or range of IC50 values (μg mL^−1)	References
MPER^1	2F5	EBV tfm^2	3.8–7.8 [132]	[133]
	4E10	EBV tfm^2	3.4 [134]	[88]
	10E8, 7H6	Neutralization assays^6	0.3–1.5 [135]	[135]
	Z13e1	Phage display	—	[57]
V1V2^3	PG9	Neutralization assays^6	0.1–9.4 [134]	[89]
	PG16	Neutralization assays^6	0.1–7.6 [136]	[89]
	CH01–04	EBV tfm^2	0.02–4.9 (CH04) [137]	[137]
	PGT141–145	Neutralization assays^6	0.2–2.1 [134]	[134]
V3^4	2G12	EBV tfm^2	2.4 [a]	[91]
	PGT121–123	Neutralization assays^6	0.03–0.05 [134]	[134]
	PGT125–131	Neutralization assays^6	0.02–0.5 [134]	[134]
	PGT135–137	Neutralization assays^6	0.2–7.8 [134]	[134]
	HGN194	B cell immort^10	0.1–3.7 [138]	[138]
CD4 bs^5	b12	Phage display	2.8 [134]	[92]
	HJ16	B cell immort^10	0.01–9.8 [138]	[138]
	VRC01–03	RSC3^7	0.3 (VRC01 [134])	[139]
	NIH45-46	gp120, 140 probes^8	0.06–1.9 [140, 141]	[140]
	3BNC55, 60, 62, 117	gp120, 140 probes^8	0.01–1.4 (BNC117 [141])	[140]
	12A12, 21, 30	gp120, 140 probes^8	0.08–2.6 (12A12 [141])	[140]
	VRC-PGV04, 4b	RSC3^7, pyrosequencing^9	0.2 (PGV04 [134])	[139]
	8ANC37, 131, 134	gp120, 140 probes^8	0.06–6.3 (131 [141])	[140]
	1B2530	gp120, 140 probes^8	0.06–9.8 [141]	[140]
	1NC3, 7, 9	gp120, 140 probes^8	0.02–1.2 (INC9[141])	[140]

1Membrane-proximal external region of gp41.
²EBV transformation of B cells.
³V1V2 site on gp120.
⁴Glycan V3 site on gp120.
⁵CD4 binding site on GP120.
⁶Neutralization assays of B cells from infected donors.
⁷Resurfaced stabilized core 3 probe.
⁸Somatic mutation primers, gp120 and gp140 probes.
⁹454 pyrosequencing to characterize additional VRC01-like antibodies from HIV-1—infected individuals.
¹⁰Efficient B cell immortalization and high throughput screening.